Astellas reports, Xtandi sales in focus for Medivation

|About: Astellas Pharma, Inc. ADR (ALPMY)|By:, SA News Editor

Astellas Pharma (ALPMY.PK) reports FQ1 consolidated net sales of ¥275.8B (.pdf), up 13.4% Y/Y.

Net sales of Xtandi — the prostate cancer treatment developed and commercialized with partner Medivation (MDVN) —  were $82M for the period, below Street estimates of $83.7M. (supplemental documents)

Xtandi faces what some say is looming threat from Janssen's acquisition of Aragon and the company's ARN-509.